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Introduction. The continuously improving cancer detection at an early stage and improving survival rates have been 
observed and, therefore, patients are predisposed to detection of multiple primaries. It has been reported that the 
incidence of multiple primaries in breast cancer patients ranges from of 4% to 17%. 
Materials and methods. A group of 112 breast cancer patients with synchronous malignancies was presented. They 
constituted 0.09% of patients (118,952 cases) who were treated for breast cancer at the same time period, and made 
up 3.5% of all patients (3,176 cases) with multiple primary cancers, and 21.7% of all patients (517 cases) with breast 
cancer who developed multiple primaries. 
Results. The most frequent type of synchronous primary malignancy was breast cancer (63.4%) and 90.1% of them 
were diagnosed at the same time or within one month following the first breast cancer diagnosis. Among cases of 
non-breast synchronous primaries, female genital organ malignancies were predominant (36.6%). Synchronous breast 
cancer was diagnosed significantly earlier than non-breast cancers (mean time was 0.4 and 1 month, respectively, 
p = 0.0123). Better results in the group with synchronous contralateral breast cancer in comparison to synchronous 
breast and non-breast cancer were observed (5-year overall survival rates were 90.9% and 66.3%, respectively, and 
5-year disease-free survival rate — 62.5% and 51.3%, respectively). 
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Introduction 
Significant progress has been observed in the preven-
tion, diagnosis and therapy of cancers. Screening program-
mes and improvements in diagnostic methods result in 
cancer being detected at an earlier stage and, moreover, the 
advances in treatment methods yield an increase the overall 
survival of cancer patients. In consequence, the occurren-
ce of multiple independent primary cancers in the same 
patient is still growing and ranges from 1% to 18% [1–7].
The definition of multiple primary cancers is based on 
the classic criteria of Warren and Gates which include: (i) 
the site of origin, (ii) the morphology and histology of tu-
mours, and (iii) the amount of time passed since the initial 
diagnosis. This means that tumours arise in other organs 
than the independent primaries, each tumour has to be 
histologically distinctive and the possibility of metastasis 
or recurrence must be excluded [8, 9]. Considering the time 
of occurrence, multiple primary cancers generally fall into 
the synchronous or metachronous [8–10]. According to 
the International Agency for Research on Cancer (IARC), 
the diagnosis of synchronous primaries is made within an 
interval of less than 6 months [8]. 
Multiple primary cancers are categorized according to 
predominant etiologic influences: treatment-related, syn-
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dromic and those due to shared etiologic factors [11]. Causal 
mechanisms of their development include the following: (i) 
host factors – genetic (BRCA mutations, Li-Fraumeni syndro-
me), hormonal, prior cancer diagnosis and treatment expo-
sures, (ii) lifestyle factors such as alcohol and tobacco use 
(risk factors for several cancer types), and (iii) environmental 
influences – geography (areas of increased radon exposure), 
pathogens (human papilloma virus or Epstein-Barr virus 
infections) and occupational factors [1, 3, 8, 10, 12–14]. 
Breast cancer is the most common cancer in women; in 
Poland 17,400 new cases of breast cancer (which constitu-
ted 21.7% of all cancers in 2014) were diagnosed in [15]. In 
these patients, continuously improving detection at an early 
stage and improving survival rates have been observed and, 
therefore, these patients are predisposed to detection of 
multiple primaries. It has been reported that the incidence 
of multiple primaries in breast cancer patients ranges from 
of 4% to 17% [5, 7, 10, 16].
The risk of developing multiple primary malignancies 
in breast cancer patients is associated with positive family 
history, suppressor gene mutation (BRCA1, BRCA2, PTEN, 
TP53), age, body weight, alcohol intake, hormonal repla-
cement therapy and breast cancer therapy (especially for 
metachronous primaries) [14, 17, 18]. 
Lee et al. showed that synchronous malignancies de-
veloped in 23.8% of breast cancer patients and the most 
frequent were malignancies located in the thyroid gland 
(71% cases) and in the gynaecologic tract (9.7%) [8]. 
The purpose of this study was (i) to present the characte-
ristics of breast cancer patients with synchronous primaries 
in relation to the type of synchronous primaries (breast and 
breast versus breast and non-breast) and (ii) to evaluate 
the outcomes and the impact of the type of synchronous 
cancers on survival rate.
Materials and methods
In this paper, synchronous malignancies are defined 
as primaries diagnosed at the same time or following the 
diagnosis of breast cancer in a time interval shorter than 
6 months. 
Patient population
Between 1965 and 2014, synchronous malignancies 
(in compliance with the above definition) were diagnosed 
in 112 breast cancer patients who were treated at Maria 
Skłodowska-Curie Memorial Cancer Centre and Institute of 
Oncology in Kraków. These patients constituted 0.09% of all 
patients (118,952 cases) who were treated for breast cancer 
in this time period, and they made up 3.5% of all patients 
(3,176 cases) with multiple primary cancers and 21.7% of 
all patients (517 cases) with breast cancer who developed 
multiple primaries. 
Table I presents the types of synchronous malignancies 
and Figure 1 presents the time interval between the diag-
nosis of breast cancer and synchronous malignancy in the 
analysed group of 112 breast cancer patients. 
The mean time interval between diagnosis of breast 
carcinoma and synchronous cancers was 0.6 ± 1.1 month 
(range: 0–5 months). More than 80% of synchronous ma-
lignancies were diagnosed at the same time or during the 
first month following breast cancer diagnosis.
The most frequent type of synchronous primary mali-
gnancy was breast cancer (71 cases — 63.4%). In 64 cases, 
this type of second synchronous cancer was diagnosed at 
Table I. The types of synchronous primary cancers in 112 patients with breast cancer 
Diagnosis of synchronous cancers ICD-10 code No. of cases %
Total 112 100.0
Breast cancer (in contralateral breast) C50 71 63.4
Female genital organ cancers: 15 13.4
Cervical uteri cancer
Endometrial cancer
Ovarian cancer
C53
C54
C56
10
1
4
8.9
0.9
3.6
Digestive organ cancers: 2 1.8
Stomach cancer
Rectal cancer
C16
C20
1
1
0.9
0.9
Skin cancer C44 11 9.8
Lung cancer C34 1 0.9
Urinary tract cancers: 4 3.6
Kidney cancer
Urinary bladder cancer
C64
C67
3
1
2.7
Thyroid cancer C73 3 0.9
Lymphatic tissue neoplasms C81, C85, C91 4 3.6
Laryngeal cancer C32 1 0.9
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the same time or within one month following first breast 
cancer diagnosis. Among 41 cases of non-breast synchro-
nous cancers, female genital organ malignancies were pre-
dominant (15 cases — 36.6%).
Statistical methods
In the studied population, two groups were distingu-
ished: patients with synchronous bilateral breast cancer and 
patients with synchronous non-breast cancer. The compa-
rison of these groups was performed in order to assess the 
relation to frequency of the analysed factors with the use of 
the Pearson’s Chi-square test for independence (for categori-
zed variables) and variance analysis with Student’s t-test (for 
continuous variables). Overall survival rate and disease-free 
survival rate were evaluated with the Kaplan-Meier method, 
and the log-rank test was applied to assess the influence 
of type of synchronous cancers on the evaluated results.
All calculations were performed by STATISTICA v.12 so-
ftware (StatSoft, Inc. Tulsa, OK, USA) and the significance 
level at α = 0.05 was adopted for all statistical analyses. 
Results
Patient characteristics and comparison
The mean age at diagnosis of breast cancer was 61.5 ± 
12.8 years (range: 30 — 85, median: 62 years). Age over 50 
years was noted in 90 cases (80.4%). Positive cancer history 
was found in 47 patients (42%) including 16 cases (34%) with 
breast cancer history. Synchronous breast cancer appeared 
in 33 patients with positive family history (70%) and in 11 
patients with breast cancer family history (68.8%). Benign 
breast diseases and/or hormonal disturbances were found 
in 8 individuals (7.2%). 
Because patients with breast cancer and synchronous 
cancers were managed over a period of 49 years, the dia-
gnostic methods and the spectra of treatment changed 
along with the indications. Nevertheless, surgery was the 
primary treatment modality of breast cancer. Because in 
the presented group of 112 patients with breast cancer 
and synchronous cancers in 71 cases synchronous bilateral 
breast cancer was diagnosed, therefore, in our material 
in 112 patients 183 breast primary tumours were found. 
Radical mastectomy was performed in 131 breast tumours 
(71.6%), whereas 52 tumours (28.4%) underwent breast-
-conserving surgery. The following adjuvant therapy was 
applied: postoperative radiotherapy (77 breast tumours — 
42.1% in 55 patients — 49.1%), chemotherapy (51 patients 
— 45.5%) and hormonotherapy (87 patients — 77.7%), 
which in 85 patients (75.9%) was combined with tamoxifen. 
In some cases, multimodal treatment was performed in an 
adjuvant setting.
Table II presents the characteristics of 112 patients with 
breast cancer and synchronous primary malignancies and 
their comparison in relation to the type of synchronous 
primary cancers: breast and breast cancers versus breast 
and non-breast cancers. 
Synchronous breast cancer was diagnosed significantly 
earlier than non-breast cancers; mean time was 0.4 and 1 
month, respectively (p = 0.0123) after first breast cancer.
There were no significant differences between the two 
analysed patients’ groups (synchronous primaries: breast 
and breast cancer versus breast and non-breast cancer) in re-
lation to epidemiological, clinical and pathological features. 
Survival and outcomes
The follow-up period after the diagnosis of breast can-
cer ranged from 2 to 371 months with a mean value of 
78.2 ± 72 months and a median of 56.5 months. Table III 
presents the outcomes which developed during clinical ob-
servation. The mean time of these outcomes was as follows: 
14.9 ± 13.9 months (for locoregional recurrence), 46.6 ± 44.2 
months (for distant metastases) and 41.1 ± 33.5 months (for 
metachronous carcinomas) after diagnosis of breast cancer. 
Patients with synchronous contralateral breast cancer had a 
tendency to more frequent development of distant metas-
tases (32.4% patients vs 13.8% patients with synchronous 
breast and non-breast cancer, p = 0.07776, Chi2 test). How-
ever, there were no significant differences (p > 0.05, Chi2 
test) between the two analysed groups in relation to the 
development of locoregional recurrences or metachronous 
(third and fourth) primaries. 
During the follow-up period 28 patients (25%) died, 
and the causes of death were as follows: breast cancer (13 
cases), non-breast primaries (6 cases), coexistent non-cancer 
internal disease (3 cases), and unknown (6 cases).
The estimated 5-year and 10-year survival rates were 
81% and 65.3% (for overall survival) and 58.3% and 44.9% 
(for disease-free survival).
Figure 2 shows the probability of overall survival (a) and 
disease-free survival (b) in relation to the type of synchro-
nous primaries (synchronous contralateral breast cancer 
versus breast and non-breast cancer).
Figure 1. The time interval between the diagnosis of breast cancer 
and synchronous malignancy in 112 patients
0
10
20
30
40
50
60
N
um
be
r o
f p
at
ie
nt
s
< 1 month
breast and breast
breast and non-breast
1 month 2 months 3 months 4 months 5 months
339
Better results in the group with synchronous contralate-
ral breast cancer in comparison to synchronous breast and 
non-breast cancer were observed (5-year overall survival 
rates were 90.9% and 66.3%, respectively, and 5-year dise-
ase-free survival rate — 62.5% and 51.3%, respectively), but 
these observations were statistically nonsignificant.
Discussion
Published data indicate that 4–17% of breast cancer 
patients develop multiple primary malignancies and, ac-
cording to Lee et al., synchronous primaries were dia-
gnosed in 24% of cases [5, 7, 8, 10, 16]. The group of 112 
patients with breast cancer and synchronous malignancies 
presented in this study constituted 21.7% of all patients 
with breast cancer who developed other primaries in the 
analysed period. It is interesting that 11 (9.8%) of our breast 
cancer patients with synchronous malignancies developed 
metachronous malignancies during the follow-up period, 
in comparison to 2.8% observed in patients analysed by 
Lee at al. [8].
Our observation showed that the most frequent syn-
chronous neoplasms were contralateral breast cancer (71 ca-
ses — 63.4%) and genital organ cancer (15 cases — 13.5%), 
of which cervical uterine cancer was predominant (8.9%).
Some literature data showed that a lobular component 
of breast carcinoma was associated with an almost 2-fold 
increase in the risk of developing contralateral breast can-
cer, especially synchronous bilateral breast cancer [19–21]. 
Table II. The characteristics of 112 patients with breast cancer and synchronous malignancies and its comparison in relation to the type of 
synchronous primary cancers: breast and breast cancers versus breast and non-breast cancers
Parameters Group 
N = 112 (100%)
Synchronous cancers p
breast and breast  
N = 71 (100%)
breast and non-breast 
N = 41 (100%)
mean time between breast and synchronous cancers 
[months] 0.6 ± 1.1 0.4 ± 0.9 1.0 ± 1.3 0.0123a
Age: mean value [years] 61.5 ± 12.8 60.8 ± 12.9 62.6 ± 12.7 0.4909a
≤ 50
> 50
22 (19.6%)
90 (80.4%)
15 (21.1%)
56 (78.9%)
7 (17.1%)
34 (82.9%)
0.6030
Menopausal status:
premenopausal
postmenopausal
47 (42%)
65 (58%)
31 (43.7%)
40 (56.3%)
16 (39%)
25 (61%)
0.6319
Family history of cancers:
negative
breast cancers
other cancers
65 (58%)
16 (14.3%)
31 (27.7%)
38 (53.5%)
11 (15.5%)
22 (31%)
27 (65.9%)
5 (12.2%)
9 (22%)
0.4392
Breast disease and other symptoms:
none
benign breast disease
hormonal disturbances
BRCA1/2 mutation
102 (91.2%)
2 (1.8%)
6 (5.4%)
2 (1.8%)
65 (91.6%)
1 (1.4%)
3 (4.2%)
2 (2.8%)
37 (90.2%)
1 (2.4%)
3 (7.3%)
0
0.61970
Histological type:
ductal
lobular
other*
84 (75%)b
8 (7.1%)b
20 (17.9%)b
57 (80.3%)b
6 (8.5%)b
8 (11.3%)b
27 (65.9%)
2 (4.9%)
12 (29.3%)
0.0573
Stage breast cancer:
pT1-2
pT3-4
89 (79,5%)b
23 (20.5%)b
59 (83.1%)b
12 (16.9%)b
30 (73.2%)
11 (26.8%)
0.2102
pN0
pN+
60 (53.6%)b
52 (46.4%)b
38 (53.5%)b
33 (46.5%)b
22 (53.6%)
19 (46.3%)
0.9888
Mean number of pN+ 5.7 ± 6.0 5.3 ± 5.8 6.2 ± 6.4 0.6047a
Treatment methods:
radiotherapy 55 (49.1%)b 40 (56.3%)b 15 (36.6%) 0.0440
chemotherapy 51 (45.5%) 36 (50.7%) 15 (36.6%) 0.1484
tamoxifen 85 (75.9%) 57 (80.3%) 28 (68.3%) 0.1530
*other types of breast cancer: medullary, mucinous, metaplastic, apocrine, tubular, inflammatory, Paget’s disease of the nipple, papillary; a p value from 
t-Student test, other p for chi-square test; bpresence of the parameter in one breast cancer at least (patients with synchronous bilateral breast cancer)
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Our observations confirmed the tendency of developing 
synchronous contralateral breast cancer in lobular breast 
carcinoma patients; in 75% of cases of lobular breast carci-
noma, synchronous contralateral breast cancer developed. 
Claus et al. observed that patients with lobular breast car-
cinoma were 2.6 times more likely to be diagnosed with 
synchronous contralateral breast cancer than patients with 
ductal breast carcinoma [22].
Published data indicate that age as well as menopausal 
status at breast cancer diagnosis are risk factors for develop-
ment of second cancer [18, 19, 21, 23–27]. Lv et al. showed 
that 84.6% patients with synchronous malignancies were 
over 50 years old [27]. In our patients, 80% of patients (90 
of 112 cases) were over 50 years old and most of them (65 
cases — 58%) were in postmenopausal status. The compari-
son to breast cancer patients who developed metachronous 
malignancies confirmed that patients with synchronous ma-
lignancies were significantly older and in postmenopausal 
status (p = 0.00001 and p = 0.00275, respectively). 
The occurrence of a second primary is associated with a 
significantly increased risk of death and significantly worse 
survival [8, 28, 29]. Particularly, this regards synchronous 
cancers [27–30]. Results published by Carmichael et al. 
showed that significantly worse overall survival is obse-
rved among patients with synchronous contralateral breast 
cancer in comparison to metachronous or unilateral breast 
cancer [31]. Quan et al published that the 5-year survival 
rate was 80.3% for synchronous breast cancer and 90.5% for 
metachronous breast cancer [32]. Our results were similar 
and 5-year survival reached 81% in all breast cancer patients 
with synchronous malignancies and 90.9% in the synchro-
nous contralateral breast cancer subgroup. The five-year 
survival rate evaluated in breast cancer patients with meta-
chronous malignancies (presented in our earlier publication) 
was 91.8% (all breast cancer patients and metachronous 
malignancies) and 92.9% in patients with metachronous 
contralateral breast cancer [33]. However, these results were 
not statistically significant (p = 0.27772, log rank test). 
The occurrence of multiple synchronous primaries is 
challenging and often causes a therapeutic dilemma in 
daily clinical practice. Therapeutic strategy for patients 
with synchronous malignancies should be discussed in a 
multidisciplinary team. The main focus in the therapeutic 
decision-making process should be placed on (i) evaluation 
of the prognosis and (ii) the chance of a curative or palliative 
approach [10].
Conclusions
1. The most frequent type of synchronous malignancy in 
patients with breast cancer is contralateral breast cancer 
(63.3% of cases) followed by female genital organ cancer 
(13.4% of cases).
2. The possibility of development of synchronous primary 
cancer in breast cancer patients indicates the necessity 
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Figure 2. The probability of overall (a) and disease-free (b) survival 
rates in relation to type of synchronous malignancy in 112 patients 
treated for breast cancer
Table III. The outcomes in 112 patients with breast cancer and 
synchronous malignancies
Outcomes No. of patients % 
Recurrence at chest wall 10 8.9
Distant metastases 30 26.8
bones
liver
lungs
lymph nodes
brain
skin 
13
7
5
4
3
1
11.6
6.3
4.5
3.6
2.7
0.9
Metachronous cancers 11 9.8
breast cancer
endometrial cancer
ovarian cancer
skin cancer
kidney cancer
bladder cancer*
Hodgkin’s lymphoma
ocular melanoma
biliary tract cancer*
1
2
1
2
1
1*
1
1
1*
0.9
1.8
0.9
1.8
0.9
0.9*
0.9
0.9
0.9*
*as 4th cancers, and remain – as 3rd morbidity
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of conducting precise diagnostic procedures, because 
detection of coexistent cancers influences the choice of 
optimal treatment strategy. 
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